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bone-specific metastasis. The impor-
tance of these data, in our opinion, lies
not with the magnitude of their prognostic
significance. Breast cancer is now replete
with prognostic gene signatures, from
young women, primary tumors versus
metastases, classes of tumors, wound
signatures, etc. (Chang et al., 2005;
Sorlie et al., 2001; van ’t Veer et al.,
2003). These data confirm the relevance
of the lung-specific genes identified in a
single model system to the heterogeneity
of human disease.
Using microarray expression analy-
sis of primary tumors from 82 patients
from Memorial Sloan-Kettering Cancer
Center, the predictive value of each of
the 54 genes within their experimentally
derived signature was determined using
a Cox proportional hazards regression
model. Relatively few of the functional
lung-specific genes were significant. Of
the genes modulating lung-specific
metastasis as single transfectants, the 
p values were all nonsignificant
(0.569–0.833). Of the genes analyzed in
combination experiments, MMP1 and
CXCL1 retained lung-specific prognostic
significance, but others, including COX2,
SPARC, and EREG, did not. Put simply,
the functional genes were not the most
prognostic genes. It will be of interest to
determine whether the most highly prog-
nostic genes, such as latent TGF-β bind-
ing protein LTBP1, the Fascin homolog
FSCN1, and the angiopoietin-like protein
ANGPTL4, are functionally involved in
lung-specific metastasis.
Minn et al. identified several potential
players in the process of breast cancer
metastasis to lung, but a detailed mech-
anism of organ-specific homing and col-
onization has yet to be established. The
identification and validation of organ-
specific metastatic pathways should lead
to targeted therapeutics for these devas-
tating diseases.
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A series of complex and orchestrated
changes in chromosome structure are
required to ensure the proper segrega-
tion of genetic material during cell divi-
sion. A direct consequence of the double
helical structure of DNA is that, after DNA
replication during S phase, duplicated
sister DNAs become topologically entan-
gled or catenated (Wang, 2002). Sister
chromatids continue to maintain a close
association throughout G2 phase. Then,
a signal at the onset of anaphase causes
disruption of the linkage between sister
chromatids, allowing them to be separat-
ed and pulled to opposite poles of the
cell. However, a process called DNA
decatenation needs to take place to sep-
arate chromosomes that have become
entangled. This process involves DNA
strand breakage and rejoining, and
requires the enzyme Topoisomerase IIα
(TopIIα) (Wang, 2002). Cells monitor the
catenation of chromatids, and when
these are insufficiently disentangled, the
decatenation checkpoint is activated,
arresting cells in metaphase (Deming et
al., 2001). This checkpoint is separate
from the response to DNA damage
(Skoufias et al., 2004) and may be inacti-
vated in some cancers (Nakagawa et al.,
2004), leading to inappropriate cell cycle
progression, chromosome breakage, and
genomic instability.
BRCA1 is a key regulator of DNA
repair and the cell cycle in higher eukary-
otic cells, and dysfunction leads to pre-
disposition to breast and a variety of
other cancers (Wooster and Weber,
2003). BRCA1 is required for the efficient
repair of double-strand DNA breaks
(DSBs) by homologous recombination,
and BRCA1 deficiency leads to the uti-
Oh what a tangled web it weaves: BRCA1 and DNA decatenation
BRCA1 has significant roles in DNA repair and cell cycle checkpoint control, and is important in the maintenance of
genomic stability. Defects in these pathways likely underpin the cancer susceptibility of BRCA1 mutation carriers. Now, a
new function for BRCA1 in DNA decatenation—removing the tangles introduced into chromosomes as a consequence of
DNA replication—is suggested in a new paper by Lou et al. (2005) in Nature Structural and Molecular Biology. Ineffective
DNA decatenation may lead to chromosome breakage and inappropriate repair, adding to the roll call of defects in BRCA1
mutant cells.
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lization of alternative DSB repair
pathways, such as nonhomolo-
gous end joining (Turner et al.,
2005).This is responsible, at least
in part, for the genomic instability
manifest in BRCA1 deficient cells.
Additional functions for BRCA1 in
cell cycle checkpoint regulation
may also be relevant to carcino-
genesis in BRCA1 mutation carri-
ers. BRCA1 is required for the
DNA damage-induced G2 cell
cycle checkpoint, and is also
implicated in controlling the
decatenation checkpoint along
with ATR (Deming et al., 2001).
Now, Junjie Chen and colleagues
(Lou et al., 2005) provide evi-
dence for a new role for BRCA1 in
DNA decatenation itself that 
suggests a further mechanism
whereby BRCA1 deficiency might
contribute to genomic instability
(Figure 1).
The starting point of the work
of Lou et al. (2005) was the previ-
ous observation that both BRCA1
and TopIIα are present in nuclear
foci in S phase of the cell cycle,
and that some of these foci coin-
cide. After confirming this observation,
the hypothesis that BRCA1 and TopIIα
proteins physically interact was tested by
coimmunoprecipitation. This indicated
that the proteins did indeed interact,
directly or indirectly, and that the C termi-
nus of BRCA1, encompassing the two
tandemly arranged BRCT domains, 
was required for this interaction. The
BRCT domains are phospho-Serine 
or -Threonine binding motifs, which
mediate protein-protein interactions (Yu
et al., 2003; Manke et al., 2003). In
agreement with the specificity of BRCT
domains, BRCA1 only bound TopIIα that
was phosphorylated. However, it is
unclear which residue(s) within TopIIα
need to be phosphorylated to mediate
the interaction with BRCA1, nor which
kinase is responsible for phosphorylating
this residue. The issue of whether the
proteins interact directly or indirectly via
bridging proteins also needs to be
resolved.
Chromosome decatenation, which is
necessary before chromosomes can
condense and segregate, requires
TopIIα activity; treatment of cells with a
TopIIα chemical inhibitor, ICRF-193,
results in a defect in chromosome segre-
gation which manifests as the presence
of bridge-like structures at mitosis con-
taining lagging chromosomes. Similarly,
in cells that are deficient for BRCA1,
either by mutation or depletion using
siRNA, lagging chromosomes are fre-
quently observed. Importantly, BRCA1
deficiency did not induce any alterations
in cell cycle profile, nor was the mitotic
checkpoint impaired. Consistent with
BRCA1 modulating TopIIα function, 
elongated (noncondensed) and tangled
chromosomes were observed in BRCA1-
deficient cells, mirroring the effects of
TopIIα inhibition by ICRF-193. This sug-
gested a role for BRCA1 in DNA decate-
nation. In vitro assays have been
developed to measure DNA decatena-
tion activity in nuclear extracts using
kinetoplast DNA as a substrate. This
activity, present in nuclear extracts,
appears to be dependent on TopIIα, as it
is inhibited by ICRF-193. Therefore,
nuclear extracts were prepared from
BRCA1-deficient and complemented cell
lines, and these assayed for the ability to
decatenate DNA. This revealed that
BRCA1 was indeed required for the in
vitro decatenation activity present in
nuclear extracts.
One obvious way in which BRCA1
might affect the ability to decatenate
DNA was by altering levels of TopIIα pro-
tein, but this appears not to be the case.
TopIIα phosphorylation has been
recognized previously as having
a role in the regulation of TopIIα
activity, and modulation of phos-
phorylation was investigated as a
possible mechanism. A gross
change in TopIIα phosphorylation
state modulated by BRCA1 was
assayed by determining the level
of interaction with the MPM-2 
protein, which only binds to phos-
phorylated TopIIα. This was
apparently unaltered, but subtle
alterations in phosphorylation
state might not be recognized
using this method. Given the
established role of BRCA1 in
mediating phosphorylation of pro-
teins by upstream kinases in
response to DNA damage (Foray
et al., 2003), this possibility
requires further investigation.
BRCA1, in association with a het-
erodimeric partner BARD1, has
ubiquitin ligase activity, but direct
substrates of this activity have
been difficult to identify (Kerr and
Ashworth, 2001). Given that
BRCA1 is associated in cells with
TopIIα, Lou et al. examined
whether TopIIα was modified by ubiquiti-
nation in a BRCA1-dependent fashion.
In normal cells, TopIIα was apparently
modified by ubiquitin conjugation, but
this was reduced in BRCA1-deficient
cells. Ubiquitination conjugation can
affect protein degradation or modify
function or subcellular location; in this
case, conjugation did not seem to affect
the stability of TopIIα.
So what might be the effects 
of BRCA1-mediated ubiquitination of
TopIIα? The possibility was explored that
this altered the subnuclear location of
the TopIIα and in particular association
of the protein with chromatin. Unmodified
TopIIα was more tightly associated with
chromatin than the ubiquitinated form,
and chromatin associated TopIIα
was less enzymatically active in the
decatenation assay described above.
Therefore, there appears to be a correla-
tion between BRCA1-dependent TopIIα
ubiquitination and TopIIα activity, the
implication being that BRCA1 deficiency
reduces TopIIα activity, and this induces
the decatenation defect.
Despite providing intriguing insight
into a new way in which BRCA1 deficien-
cy can induce genomic instability, several
questions remain, particularly relating to
the exact role of BRCA1 in decatenation.
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Figure 1. Cell cycle-related functions of BRCA1
Double strand DNA breaks or arrested or collapsed replica-
tion forks occurring in S phase are repaired in part by
BRCA1-dependent homologous recombination (Turner et
al., 2005). BRCA1 acts in the intra-S and G2/M phase cell
cycle checkpoints (Xu et al., 2001). BRCA1 is required for
efficient decatenation of chromatids (Lou et al., 2005) and
the checkpoint which monitors whether this has occurred
(Deming et al., 2001).
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First, does the BRCA1/BARD1 het-
erodimer directly ubiquitinate TopIIα?
Second, does ubiquitination of TopIIα
abrogate chromatin association, or does
the protein simply become ubiquitinated
when it becomes less tightly bound to
chromatin? Finally, the defect in DNA
repair by homologous recombination in
BRCA1-deficient cells provides an
avenue for potential novel therapeutic
approaches (Farmer et al., 2005). It may
be that the decatenation defect caused by
BRCA1 deficiency may provide an addi-
tional route to specifically target tumors
arising in BRCA1 mutation carriers.
Alan Ashworth1,*
1The Breakthrough Breast Cancer
Research Centre
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